Functional assays are in the truest sense precision medicine; matching a patient to a drug by directly testing their live tissue. The hypothesis is simple, yet in a personalized healthcare approach dominated by population scale genomics, the utilization of functional assays is limited. There exists a great opportunity to expand precision medicine beyond genomics, ultimately bringing better treatment options and the potential for greater outcomes to patients in need.
Bringing together a unique mix of pharmaceutical, academic and technology leaders, the series is must attend for those interested in the use of assaying technology to further biomarker discovery, drug R&D and personalized healthcare outcomes.
Through guest speakers, interactive panel discussions and Q&A sessions, the series will focus on these key topics:
- Demonstrating the clinical utility of functional precision medicine testing
- Implementing functional testing in precision medicine clinical trials
- Accelerating the application of functional testing
- Addressing stakeholder, educational and investment challenges for functional precision medicine
Meeting ID: 936 9981 1786
If joining by phone:
- +1 312 626 6799 US (Chicago)
- +1 929 205 6099 US (New York)
- +1 301 715 8592 US (Germantown)
- +1 346 248 7799 US (Houston)
- +1 669 900 6833 US (San Jose)
- +1 253 215 8782 US (Tacoma)
January 13, 2021 | 11:00 AM EST
Scott Manalis, PhD of Massachusetts Institute of Technology
"Single-cell mass as a clinical tool for guiding treatment decisions"
Dr Patrick Bhola, Dana-Farber Cancer Institute
"Rapid ex vivo testing using high content dynamic BH3 profiling may identify active therapies in solid tumors"
December 9, 2020 | 11:00 AM EST
Vinayak Prasad, MD, MPH, University of California, San Francisco
"The Limits of Genome Oncology"
Julio Saez-Rodriquez, PhD, University of Heidelberg, Germany
"Patient‐specific network models from screenings on biopsies for personalized medicine"
November 11, 2020 | 11:00 AM EST
Alana L. Welm, PhD, Huntsman Cancer Institute
"Functional precision medicine for metastatic breast cancer"
Santhosh Balasubramanian, Notable Labs
"Designing precision oncology trials to develop and validate drug sensitivity assays"
October 14, 2020 | 11:00 AM EST
Sarah J. Hill, MD, PhD, Dana-Farber Cancer Institute
"Studying the anti-tumor immune response in novel patient-derived high grade serous ovarian cancer organoid co-cultures"
Astrid Margossian, MD, PhD, SEngine Precision Medicine
"Predictive Clinical Value of a CLIA-Approved Organoid Based Drug Sensitivity Test"
September 9, 2020 | 11:00 AM EST
Lawrence Boise, PhD - Emory University
"Functional and phenotypic analysis of venetoclax sensitivity in multiple myeloma."
Olli Kallioniemi - Karolinska Institute
" - Functional precision cancer medicine: molecular insights and clinical implementation in AML and beyond"
August 12, 2020 | 11:00 AM EST
Dr. Zenz Thorsten - University of Zurich
“Drug-perturbation-based stratification of blood cancer”
Dr. Hervé Tiriac - UCSD Moores Cancer Center
"Pancreatic Cancer Patient-Derived Organoids as a Tool for Personalized Medicine"
July 8, 2020 | 11:00 AM EST
Caroline Heckman, PhD, Research Director, Institute for Molecular Medicine, Finland
“Predicting drug combination efficacy in hematological malignancies by multi-parametric functional analysis”
Gregory Vladimer, PhD, CSO, Allcyte
"High content microscopy of primary patient material and AI in translational research and precision medicine"